Atropine pharmaceutical compositions
US-12036217-B2 · Jul 16, 2024 · US
US11253507B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11253507-B2 |
| Application number | US-201816487423-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 20, 2018 |
| Priority date | Feb 21, 2017 |
| Publication date | Feb 22, 2022 |
| Grant date | Feb 22, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Methods of preventing or delaying onset of myopia in pre-myopic patients and also methods of reducing or preventing progression of myopia in patients having low myopia through the use of compositions comprising less than 0.025% of atropine are disclosed.
Opening claim text (preview).
What is claimed is: 1. A method for preventing or delaying the onset of myopia comprising administering to a subject in an eye a composition comprising from about 0.001% to less than 0.025% atropine, wherein the Spherical Equivalent (SE) of the eye is a positive value or a negative value less than —0.5D before administration of the composition. 2. The method of claim 1 , wherein the atropine is present in the form of atropine salt. 3. The method of claim 2 , wherein the atropine salt is atropine sulfate or atropine acetate. 4. The method of claim 1 , wherein the composition comprises about 0.01% atropine. 5. The method of claim 1 , wherein the composition comprises about 0.001% to 0.0249% atropine. 6. The method of claim 1 , wherein the composition is administered every other day, or at least once daily, or at least twice daily. 7. The method of claim 1 , wherein each administration is performed by instilling at least one drop, at least two drops, or at least three drops to the eye, wherein each drop contains about 20-100 microliter liquid. 8. The method of claim 1 , wherein the administration continues for the period of at least six months, one year, two years, three years, four years, five years, six years, seven years, ten years or longer. 9. The method of claim 1 , wherein the composition further comprises at least one pharmaceutically acceptable excipient. 10. The method of claim 1 , wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of benzalkonium chloride and hydroxypropyl methylcellulose. 11. The method of claim 10 , wherein the benzalkonium chloride is present in the composition at a concentration of about 0.01% or wherein the hydroxypropyl methylcellulose is present in the composition at a concentration of about 1%. 12. The method of claim 1 , wherein the composition contains no preservatives. 13. The method of claim 1 , wherein the subject is at least 5 years old. 14. The method according to claim 1 , wherein the Spherical Equivalent (SE) of the eye is within the range of from +1.00D to −0.49D before administration of the composition. 15. The method of claim 1 , wherein the subject has no astigmatism or has astigmatism of not more than 1.50D as measured by cycloplegic or non-cycloplegic autorefraction before administration of the composition, or wherein the pupil of the eye has no dilation or a dilation of no greater than 0.2 mm during the period of administration of the composition, or wherein the eye has no loss of accommodation or a loss of accommodation of no greater than 9D. 16. The method of claim 1 , wherein the subject has at least one myopic parent. 17. The method of claim 1 , wherein the onset of myopia is delayed for greater than 6 months, 12 months, 18 months, two years, three years, five years, six years, eight years, or longer. 18. The composition of claim 5 , wherein the composition comprises about 0.001%, about 0.002%, about 0.003%, about 0.004%, about 0.005%, about 0.006%, about 0.007%, about 0.008%, about 0.009%, about 0.01%, about 0.011%, about 0.012%, about 0.013%, about 0.014%, about 0.015%, about 0.016%, about 0.017%, about 0.018%, about 0.019%, about 0.02%, about 0.021%, about 0.022%, about 0.023%, about 0.024%, about 0.0245% or about 0.0249% atropine. 19. The method of claim 14 , wherein the SE is measured by Autorefractor after administration of cycloplegia. 20. The method of claim 13 , wherein the subject is between 5 and 9 years old.
Surgical instruments for veterinary use · CPC title
for accommodation disorders, e.g. myopia · CPC title
Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide · CPC title
8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine · CPC title
Cellulose; Derivatives thereof · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.